spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  acute lymphoblastic leukemia 

 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2021
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Jul 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2018
Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 17 Jun 2016
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
Biopharmaceuticals Distribution
 HSMN NewsFeed - 2 Jun 2016
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 4 Feb 2016
Phase 3 Study of BLINCYTO(R) (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Amgen's BLINCYTO(R) (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Jul 2015
Xencor Appoints Yujiro S. Hata to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Apr 2014
FDA Approves New Liquid Form Of Treatment For Patients With Acute Lymphoblastic Leukemia (ALL) As Part Of A Combination Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2013
Spectrum Pharmaceuticals Acquires Talon Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Oct 2012
Clinical Study Validates Sequenta’s LymphoSIGHT(TM) Platform as More Sensitive Alternative to Flow Cytometry for Cancer Detection
Diagnostics Oncology
 HSMN NewsFeed - 22 May 2012
Talon Therapeutics Appoints Head of Commercial Operations and Planning
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Feb 2012
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC(R) for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 26 Jan 2012
Amgen to Acquire Micromet
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 5 Dec 2011
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Nov 2011
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jun 2011
Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2010
EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Dec 2009
Hana Biosciences Appoints Howard Furst, M.D., M.B.A., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Dec 2009
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 18 Nov 2009
Asuragen Signs Development and Worldwide Distribution Agreement with Life Technologies
Diagnostics Oncology Distribution
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2009
EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2008
FDA Approves Genzyme's Mozobil
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Sep 2008
DOR BioPharma Forms orBec(R) European Medical Advisory Board
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Jul 2008
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jun 2008
Hana Biosciences Receives U.S. Orphan Drug Designation for Marqibo for the Treatment of Metastatic Uveal Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2008
EUSA Pharma Completes Acquisition Of Cytogen Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2008
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2008
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Mar 2008
EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Feb 2008
ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
Biopharmaceuticals Regulatory Drug Delivery
 HSMN NewsFeed - 18 Dec 2007
Judith A. Hemberger Elected to Novacea's Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2007
Micromet Announces Changes in Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2007
BioCryst Provides Forodesine HCl Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Nov 2007
Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Sep 2007
Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Biopharmaceuticals Surgery Acquisitions
 HSMN NewsFeed - 24 Aug 2007
Hana Biosciences Appoints Dr. Steven R. Deitcher President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Aug 2007
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Aug 2007
Bioenvision Provides Evoltra(R) (clofarabine) Regulatory Update
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jun 2007
CombiMatrix Molecular Diagnostics Launches HemeScan(TM) Ploidy Test for the Management of Acute Lymphoblastic Leukemia
Diagnostics Oncology
 HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Mar 2007
BioCryst Provides Fodosine(TM) Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2007
Bioenvision Files with EMeA for Label Extension of Evoltra(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Feb 2007
EMEA Grants Orphan Drug Designation to BioCryst's Fodosine(TM) for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jan 2007
BioCryst Initiates Pivotal Fodosine(TM) Phase IIb Clinical Trial in Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jan 2007
Hana Biosciences Receives Orphan Drug Designation for Marqibo(R) (Vincristine Sulfate Liposomes Injection) for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Dec 2006
Bioenvision Provides Update on Evoltra(R) European Regulatory Activities
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Dec 2006
Hana Biosciences Announces Filing of a Special Protocol Assessment (SPA) for Marqibo(R) (Vincristine Sulfate Liposomes Injection) in Relapsed Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
New Evoltra(R) Data Shows Impressive Response and Survival Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Results of Clinical Trial Program Suggest Fodosine(TM) Demonstrates Clinical Activity in Certain Types of Leukemia and Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2006
BioCryst's Fodosine(TM) Granted Orphan Status In Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2006
Latest Data Confirm Benefits of Evoltra(R) in Children with Relapsed/Refractory Acute Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Sep 2006
Bioenvision to Expand into Japan and Southeast Asia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2006
Researchers Uncover Clues That May Lead To Better Therapies For Children With T-Cell Acute Lymphocytic Leukemia
Oncology
 HSMN NewsFeed - 14 Sep 2006
Bioenvision to Formally Launch Evoltra(R) Throughout Europe
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jun 2006
Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2006
Hana Biosciences Receives Orphan Drug Designation for Talotrexin (PT-523), For the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 May 2006
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 70

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 70 additional stories matching:
acute lymphoblastic leukemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.